Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Joshua Barnett & Sofia Pappa. (2023) Switching from Monthly to Three-Monthly Long-Acting Injectable Paliperidone: A Survey on Subjective Satisfaction and Safety. Patient Preference and Adherence 17, pages 1603-1610.
Read now
Read now
Ruth Milz, Carmela Benson, Karl Knight, Jose Antunes, Dean Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal & John M Kane. (2023) The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric Disease and Treatment 19, pages 531-545.
Read now
Read now
Stefano Bramante, Gabriele Di Salvo, Giuseppe Maina & Gianluca Rosso. (2023) Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs. Neuropsychiatric Disease and Treatment 19, pages 519-530.
Read now
Read now
Juan Antonio García-Carmona & Sofia Pappa. (2023) Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal. Drug, Healthcare and Patient Safety 15, pages 113-123.
Read now
Read now
Giovanna Cirnigliaro, Vera Battini, Rita Cafaro, Giulia Mosini, Simone Vanzetto, Tiziano Prodi, Monica Macellaro, Rodolfo Leuzzi, Dario Conti, Carla Carnovale & Bernardo Dell’Osso. (2023) Barriers to the use of three-month Paliperidone Palmitate formulation: a study from an Italian real-world setting. Expert Review of Neurotherapeutics 23:11, pages 1031-1039.
Read now
Read now
S Kor Spoelstra, Jojanneke Bruins, Leonie Bais, Paul Seerden, Stynke Castelein & Henderikus Knegtering. (2022) One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients’, Relatives’, and Mental Health Professionals’ Perspectives. Patient Preference and Adherence 16, pages 615-624.
Read now
Read now
Ibrahim Turkoz, Mehmet Daskiran, H Lynn Starr, Dean Najarian, Oliver Lopena, Camilo Obando, Alexander Keenan, Carmela Benson & Srihari Gopal. (2022) Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections. Neuropsychiatric Disease and Treatment 18, pages 1927-1937.
Read now
Read now
Martin Lambert, Pedro Sanchez, Paul Bergmans, Srihari Gopal, Maju Mathews, Annette Wooller & Katalin Pungor. (2020) Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia. Neuropsychiatric Disease and Treatment 16, pages 3197-3208.
Read now
Read now
Laura Orsolini, Domenico De Berardis & Umberto Volpe. (2020) Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opinion on Drug Safety 19:8, pages 981-998.
Read now
Read now
Leslie Citrome, Yangchun Du & Peter J Weiden. (2019) Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm. Neuropsychiatric Disease and Treatment 15, pages 2639-2646.
Read now
Read now
Articles from other publishers (15)
Indranath Chatterjee & Shilpa Chatterjee. (2023) Investigating the symptomatic and morphological changes in the brain based on pre and post-treatment: A critical review from clinical to neuroimaging studies on schizophrenia. IBRO Neuroscience Reports 14, pages 366-374.
Crossref
Crossref
Hilary PhelpsDee LinAlex KeenanAditya RajuDanmeng HuangChih-Yuan ChengCarmela Benson. (2023) Budget impact of introducing once-every-6-months paliperidone palmitate in US health care plans. Journal of Managed Care & Specialty Pharmacy 29:3, pages 303-313.
Crossref
Crossref
Jane Loftus, Andrew Yaworsky, Carl L. Roland, Diane Turner-Bowker, Megan McLafferty, Sylvia Su & Roger E. Lamoureux. (2022) Experience of switching from a daily to a less frequent administration of injection treatments. PLOS ONE 17:11, pages e0278293.
Crossref
Crossref
Young-Chul Chung, Yen Kuang Yang, Ahmad Hatim Sulaiman, Paul Bergmans & Wilson Tan. (2022) Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting. Clinical Psychopharmacology and Neuroscience 20:3, pages 427-439.
Crossref
Crossref
Dean Najarian, Panna Sanga, Steven Wang, Pilar Lim, Arun Singh, Mary Jane Robertson, Kristin Cohen, Alain Schotte, Ruth Milz, Raja Venkatasubramanian, Huybrecht T’Jollyn, David P Walling, Silvana Galderisi & Srihari Gopal. (2022) A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia. International Journal of Neuropsychopharmacology 25:3, pages 238-251.
Crossref
Crossref
Massimo Carlo Mauri, Gemma Franco, Alessandro Minutillo, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Sara Baldelli & Dario Cattaneo. (2022) The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly. Journal of Clinical Psychopharmacology 42:1, pages 23-30.
Crossref
Crossref
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
1
224
.
Katalin Pungor, Pedro Sanchez, Sofia Pappa, Jerome Attal, Karolina Leopold, Geertje Steegen, Antonio Vita, Carol Marsella, Caroline Verrijcken, Marjolein Lahaye & Annette Wooller. (2021) The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia. BMC Psychiatry 21:1.
Crossref
Crossref
Shuichi Suetani, Dan Siskind, Andrea Phillipou, Anna Waterreus, Vera A Morgan & David Castle. (2021) Characteristics of people on long-acting injectable antipsychotics in Australia: Data from the 2010 National Survey of High Impact Psychosis. Australian & New Zealand Journal of Psychiatry 55:10, pages 958-975.
Crossref
Crossref
Juan J. Fernández-Miranda, Silvia Díaz-Fernández, Domenico De Berardis & Francisco López-Muñoz. (2021) Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia. Journal of Clinical Medicine 10:7, pages 1408.
Crossref
Crossref
Natalia N. Petrova & Valeria S. Serazetdinova. (2020) Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia. Consortium Psychiatricum 1:2, pages 53-62.
Crossref
Crossref
Zh. B. Bibekova, E. A. Strel’cov & A. S. Makarchuk. (2020) APPLICATION OF ANTIPSYCHOTICS OF LONG-TERM ACTION IN SCHIZOPHRENIA. Medical Herald of the South of Russia 11:1, pages 6-13.
Crossref
Crossref
Katalin Pungor, Vasilis P. Bozikas, Robin Emsley, Pierre-Michel Llorca, Srihari Gopal, Maju Mathews, Annette Wooller & Paul Bergmans. (2020) Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes. Therapeutic Advances in Psychopharmacology 10, pages 204512532098150.
Crossref
Crossref
Chun-Hung Chang, Hsien-Yuan Lane, Chieh-Yu Liu, Shaw-Ji Chen & Chieh-Hsin Lin. (2019) Paliperidone is associated with reduced risk of severe hepatic outcome in patients with schizophrenia and viral hepatitis: A nationwide population-based cohort study. Psychiatry Research 281, pages 112597.
Crossref
Crossref
Amanda Krogmann, Luisa Peters, Laura von Hardenberg, Katja Bödeker, Viktor B. Nöhles & Christoph U. Correll. (2019) Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectrums 24:S1, pages 38-69.
Crossref
Crossref